TX-COGNITE
17.6.2024 15:01:30 CEST | Business Wire | Press release
Cognite, the globally recognized authority in Data and AI for industry, today announced Cognite Atlas AI™, an industrial agent workbench that extends Cognite’s Industrial DataOps platform, Cognite Data Fusion®. This strategic offering is a culmination of Cognite’s extensive Industrial DataOps and innovative generative AI capabilities. Cognite Atlas AI’s low-code industrial agent builder will enable industrial organizations to use generative AI to carry out more complex operations with greater accuracy, including workflow automation and decision-making support, accelerating efficiencies that can generate tens of millions of dollars in business impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613136987/en/
Cognite Atlas AI enables low-code development of AI agents that increase the accuracy of industrial AI, accelerate efficiencies, and drive business impact (Graphic: Cognite)
Cognite Atlas AI provides domain-specific insights and automates complex, industry-relevant tasks. It reduces the cognitive load on process engineers, field workers, maintenance teams, and other data consumers while optimizing and automating business processes that increase efficiency, reduce costs, and improve operational accuracy.
Powered by Cognite’s unique combination of industry-tailored AI product capabilities, specialized industrial domain knowledge, and industrial generative AI delivery expertise, Cognite Atlas AI delivers everything necessary for asset-heavy organizations to orchestrate industrial agents on top of their private data, including:
- A library of pre-built industrial agents, as well as a low-code agent builder
- A Semantic Industrial Knowledge Graph with Context Augmented Generation (CAG)
- Industrial use case-tailored autoLLM capabilities to identify the best Large Language Model, Small Language Model, or Custom Language Model for any given industrial agent
- Easy deployment of industrial agents into Cognite Data Fusion®, Microsoft Copilot, proprietary applications, or other third-party applications
“We are seeing a shift from a singular category of models to a portfolio of models where customers have the ability to make decisions on the best models for their specific scenarios,” said Darryl Willis, Corporate Vice President Energy and Resources Industry at Microsoft. “Cognite Atlas AI brings Context Augmented Generation to Microsoft Azure OpenAI Service and, together, we are pushing the boundaries of what language models can do for industrial organizations.”
“We are thrilled to already be collaborating with customers on the cutting-edge capabilities of Cognite Atlas AI," said Geir Engdahl, Chief Product Officer and Cofounder at Cognite. "Our goal over the next 90 days is to work with all existing Cognite Data Fusion customers to unlock unprecedented value through our innovative AI solutions. At the Cognite user conference, IMPACT, happening in Houston this October, we are eager to see these customers showcase their groundbreaking AI strategies and the transformative impact they are achieving."
To learn more, visit: https://www.cognite.com/en/product/atlas
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613136987/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom